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Abstract
The multitude and abundance of macrophage-derived mediators in
rheumatoid arthritis and their paracrine/autocrine effects identify
macrophages as local and systemic amplifiers of disease. Although
uncovering the etiology of rheumatoid arthritis remains the ultimate
means to silence the pathogenetic process, efforts in under-
standing how activated macrophages influence disease have led to
optimization strategies to selectively target macrophages by
agents tailored to specific features of macrophage activation. This
approach has two advantages: (a) striking the cell population that
mediates/amplifies most of the irreversible tissue destruction and
(b) sparing other cells that have no (or only marginal) effects on
joint damage.
Introduction
Macrophages (Mφ) are of central importance in rheumatoid
arthritis (RA) due to their prominent numbers in the inflamed
synovial membrane and at the cartilage-pannus junction, their
clear activation status [1,2] (see Table 1 for overview), and
their response to successful anti-rheumatic treatment [3].
Although Mφ probably do not occupy a causal pathogenetic
position in RA (except for their potential antigen-presenting
capacity), they possess broad pro-inflammatory, destructive,
and remodelling potential and contribute considerably to
inflammation and joint destruction in acute and chronic RA.
Also, activation of this lineage extends to circulating
monocytes and other cells of the mononuclear phagocyte
system (MPS), including bone marrow precursors of the
myelomonocytic lineage and osteoclasts [2,4,5].
Thus, before a causal factor for RA is known, monocytes/Mφ
remain an attractive research focus for the following reasons:
(a) the radiological progression of joint destruction correlates
with the degree of synovial Mφ infiltration [1], (b) the thera-
peutic efficacy of conventional anti-rheumatic therapy
coincides with downregulation of MPS functions [6], (c)
therapies directed at cytokines made predominantly by Mφ
are effective in RA [7], (d) conventional or experimental drugs
can be selectively targeted to Mφ or their different subcellular
compartments (for example, [2,8]), (e) differential activation of
intracellular signal transduction pathways underlies different
Mφ effector functions [9], and (f) more specific inhibitors of
key metabolic enzymes or particular signal transduction
pathways may become available as selective targets of anti-
rheumatic therapy [9,10]. In addition, the amplifying role of
Mφ in RA has emerged so clearly that the effects of anti-
rheumatic therapy (whether specific or conventional) on
monocytes/Mφ may become an objective readout of the
effectiveness of treatment [11-13] (Stuhlmuller B, Hernandez
MM, Haeupl T, Kuban RJ, Gruetzkau A, Voss JW, Salfeld J,
Kinne RW, Burmester GR, unpublished data).
Differentiation and activation of the
mononuclear phagocyte system in
rheumatoid arthritis
Cells of the myelomonocytic lineage differentiate into several
cell types critically involved in disease (that is, monocytes/Mφ,
osteoclasts, and dendritic cells) (Figure 1a). Due to their
marked plasticity, these pathways can be influenced by an
excess/imbalance of cytokines or growth factors, resulting in
altered differentiation/maturation (Figure 1b). In RA, such
imbalances clearly occur in inflamed joints, peripheral blood,
and bone marrow (Table 2 and Figure 1b).
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Cells of the MPS show clear signs of activation, not only in
synovial and juxta-articular compartments such as the
synovial membrane or the cartilage-pannus and bone-pannus
junctions (including the subchondral bone), but also in extra-
articular compartments (for example, peripheral blood and
subendothelial space, the latter of which is the site of foam
cell formation and development of atherosclerotic plaques in
RA) (Table 2). This activation underlines the systemic
inflammatory character of RA and may contribute to the
occurrence of cardiovascular events and its increased
mortality (reviewed in [2,14,15]).
Biological functions of monocytes/
macrophages and their role in rheumatoid
arthritis
The monocyte/Mφ system represents an integral part of the
natural immune system and participates in the first-line
response against infectious agents. Another crucial contri-
bution to the body’s homeostasis is the scavenging function
of any debris generated by physiological or pathological
processes. Thus, monocytes/Mφ possess multiple and
powerful biological functions that may greatly affect onset
and development of chronic inflammatory diseases like RA
(see overview in Table 3) (reviewed in [16]).
Stimulation/regulation of monocyte/
macrophage activation in rheumatoid arthritis
The role of monocytes/Mφ in RA is conceivably the integrated
result of stimulatory, effector, dually active, and autoregulatory
mediators/mechanisms. At the tissue level, the scenario is
characterized by the influx of pre-activated monocytes, their
maturation into resident Mφ, their full activation, and their
interaction with other synovial cells. The complexity of the
interaction is the result of paracrine activation mechanisms
generated via sheer cell-cell contact as well as of numerous
autocrine mechanisms - nearly any soluble mediator shows
abnormalities. A simplified scheme of this integrated system
and the currently known mediators is provided in Figure 2.
For ease of presentation, the parts are organized as incoming
stimuli (both paracrine and soluble) (column a) and effector
molecules (column b), although autocrine loops are also
relevant (as discussed below).
Cell-cell interaction
A significant part of Mφ effector responses is mediated by
cell contact-dependent signalling with different inflammatory
or mesenchymal cells (as exemplified in the lower left
quadrant of Figure 2).
Table 1
Activation status of synovial macrophages and/or circulating monocytes in rheumatoid arthritis
Class of overexpressed molecules Molecules Known or potential function
Class II major histocompatibility  HLA-DR Presentation of antigens relevant to disease 
complex (overexpressed on Mφ) initiation or severity [93] (Stuhlmuller B, et al., 
unpublished data) (reviewed in [2])
Cytokines and growth factors For example, TNF-α, IL-1, IL-6, IL-10, IL-13, IL-15,  Mediation and regulation of local and systemic 
IL-18, migration inhibitory factor, granulocyte  inflammation and tissue remodelling (reviewed in 
macrophage colony-stimulating factor, and  [2,24,39,52])
thrombospondin-1
Chemokines and chemoattractants For example, IL-8, macrophage inflammatory  Mediation and regulation of monocyte migration
protein-1, monocyte chemoattractant protein-1,  Stimulation of angiogenesis (reviewed in [69])
and CXCL13
Metalloproteases (MMPs) MMP-9 and MMP-12 Tissue degradation and post-injury tissue 
remodelling [94,95] 
Tissue inhibitors of MMP (TIMPs) TIMP-1 Attempt to control excessive tissue destruction [96]
Acute-phase reactants For example, C-reactive protein and A-SAA  Integrated hormone-like activation of hepatocytes 
(serum amyloid A) by synovial Mφ and fibroblasts (mostly via IL-6) 
[97] (reviewed in [2]) 
Other molecules Neopterin Produced by interferon-gamma-stimulated 
monocytes/Mφ
Induces/enhances cytotoxicity and apoptosis
Acts as antioxidant [98,99]
Cryopyrin Produced by TNF-α-stimulated Mφ
Regulates nuclear factor-kappa-B and caspase-1 
activation [100]
IL, interleukin; Mφ, macrophages; TNF-α, tumor necrosis factor-alpha. Reproduced with permission from Kinne RW, Stuhlmuller B, Palombo-Kinne
E, Burmester GR: The role of macrophages in rheumatoid arthritis. In Rheumatoid Arthritis. Edited by Firestein GS, Panayi GS, Wollheim FA. New
York: Oxford University Press; 2006:55-75 [2].Page 3 of 16
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Fibroblast-macrophage interaction
Because of the prominent numbers of Mφ and fibroblasts and
their activated status in RA synovial tissue, the interaction of
these cells is critical for the resulting inflammation and tissue
damage. Indeed, the mere contact of these cells elicits the
production of interleukin (IL)-6, granulocyte macrophage
colony-stimulating factor (GM-CSF), and IL-8. The cytokine
output can be enhanced or down-modulated not only by
addition of pro-inflammatory or regulatory cytokines (for exam-
ple, IL-4, IL-10, IL-13, or IL-1 receptor antagonist [IL-1RA]),
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Figure 1
Physiological/pathological differentiation of the mononuclear phagocyte system in rheumatoid arthritis (RA). (a) Physiological differentiation of the
mononuclear phagocyte system (MPS) (steady-state cytokine and growth factor milieu). In the human MPS, monocytes (M) differentiate from a
CD34+ stem cell via an intermediate step of monoblasts. Monocytes leave the bone marrow and remain in circulation for approximately 3 days.
Upon entering various tissues, they differentiate into different types of resident macrophages (Mφ), including synovial macrophages. It is believed
that these mature cells do not recirculate, surviving for several months in their respective tissues until they senesce and die. Some circulating
monocytes retain the potential for differentiating into dendritic cells and osteoclasts (asterisk in the insert). The steady-state myeloid differentiation
involves many factors, including granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-1, IL-6, and tumor necrosis factor-
alpha (TNF-α), which are produced by resident bone marrow macrophages (reviewed in [2]). (b) Increased plasticity of myeloid differentiation and
its possible role in RA (augmented cytokine and growth factor milieu). Human bone marrow intermediate cells can differentiate into macrophages
or dendritic cells in the presence of c-kit ligand, GM-CSF, and TNF-α. TNF-α, in turn, inhibits the differentiation of monocytes into macrophages in
vitro and, together with GM-CSF, directs the differentiation of precursor cells into dendritic cells, another important arm of the accessory cell
system. Also, either IL-11 or vitamin D3 and dexamethasone induce the differentiation of bone marrow cells or mature macrophages into
osteoclasts, cells involved in the destruction of subchondral bone in RA. Osteoclasts and dendritic cells can also be derived from circulating
monocytes upon stimulation with macrophage colony-stimulating factor (M-CSF) or IL-4 plus GM-CSF. This plasticity, and its dependence on
growth factors or cytokines that are clearly elevated in peripheral blood and bone marrow of patients with RA, may explain some differentiation
anomalies in the disease and also the efficacy of some anti-rheumatic drugs. Non-specific enhancement of monocyte maturation and tissue
egression, in turn, are consistent with the known alterations in inflammation (reviewed in [2]). The differentiation paths potentially relevant to RA are
indicated by bold arrows. The jagged arrows represent possible sites of cell activation. CFU-GM, colony-forming units-granulocyte macrophage;
CFU-M, colony-forming units-macrophage; MNC, mononuclear cells; PM(N), polymorphonuclear leukocytes. Reproduced with permission from
Kinne RW, Stuhlmuller B, Palombo-Kinne E, Burmester GR: The role of macrophages in rheumatoid arthritis. In Rheumatoid Arthritis. Edited by
Firestein GS, Panayi GS, Wollheim FA. New York: Oxford University Press; 2006:55-75 [2].
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Mbut also by neutralization of the CD14 molecule [17]. Also, in
vitro, significant cartilage degradation occurs in co-cultures of
mouse fibroblasts and Mφ, a response markedly exceeding
that observed with each culture alone (reviewed in [2]).
Furthermore, purified human synovial fibroblasts co-cultured
with myelomonocytic cells induce cartilage degradation in
vitro, but with a strong contribution of soluble IL-1 and tumor
necrosis factor (TNF)-α [18].
T cell-macrophage interaction
Accessory, inflammatory, effector, and inhibitory Mφ functions
can be stimulated by fixed T cells or their plasma membranes
if T cells are pre-activated and express activation surface
molecules. In response to such interaction, monocytes
produce metalloprotease (MMP), IL-1α, and IL-1β [19,20].
Also, T cells pre-stimulated in an antigen-mimicking fashion
stimulate TNF-α and IL-10 production once in contact with
monocytes [20]. Conversely, fixed T cells stimulated in an
antigen-independent fashion (that is, with IL-15, IL-2, or a
combination of IL-6 and TNF-α, the so-called Tck cells)
induce monocyte production of TNF-α but not the anti-
inflammatory IL-10 [20,21]. These findings suggest that early
RA may reflect antigen-specific T cell-Mφ interactions [22].
Conversely, chronic RA may be associated with antigen-
independent interactions dominated by an exuberant cytokine
milieu and Tck cells. This may also explain the relative paucity
of IL-10 in the synovial membrane in chronic RA, as
discussed below.
Several ligand pairs on T cells and monocytes/Mφ have been
implicated in this interaction [20], although the importance of
individual ligand pairs, as well as the influence of soluble
mediators, remains unclear. Interestingly, T cells isolated from
RA synovial tissue show phenotypical and functional features
similar to Tck cells and the above-mentioned signal
transduction pathways differentially contribute to the
induction of TNF-α and IL-10 production in monocytes/Mφ by
co-culture with Tck cells. If applicable in vivo in RA, this
would allow selective therapeutic targeting of pro-inflam-
matory TNF-α and sparing of anti-inflammatory IL-10.
Interaction of macrophages with endothelial cells and natural
killer cells
The interaction between monocytes and endothelial cells in
RA (Figure 2), critical for the sustained influx of activated
monocytes in the synovial membrane, relies on the altered
expression of integrin/selectin pairs on the surface of the two
cell types (reviewed in [2]). Because the synovial cytokine
milieu (including the Mφ-derived TNF-α) upregulates the
expression of these ligand pairs, a self-perpetuating cycle
ensues by which sustained Mφ-derived mechanisms lead to
further influx and activation of circulating monocytes. Upon
cell contact, monokine-activated CD56bright natural killer cells
induce monocytes to the production of TNF-α, thus
representing another possible reciprocal loop of activation in
RA [23].
Soluble stimuli
Cytokine stimuli with pro-inflammatory effects on macrophages
Numerous cytokines with known or potential stimulatory
activity on monocytes/Mφ have been identified, as schemati-
cally shown in the upper left quadrant of Figure 2. A syste-
matic list of these stimuli and their known or potential
functions is provided in Table 4. Some of these mediators are
produced by monocytes/Mφ themselves and therefore
activate Mφ in an autocrine fashion, as also exemplified in
Arthritis Research & Therapy    Vol 9 No 6 Kinne et al.
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Table 2
Potential sites of myelomonocytic activation in rheumatoid arthritis and corresponding steps of macrophage intermediate or
terminal (trans)differentiation
Compartment Location Differentiation step 
Joint or juxta-articular Synovial membrane ￿ Recently immigrated monocytes
￿ Mφ (M1/M2? [64]; resident/inflammatory? [13])
￿ Dendritic cells
Cartilage-pannus junction Mφ
Subchondral bone Osteoclasts
Vascular endothelium -
Extra-articular Peripheral blood Circulating monocytes
Bone marrow ￿ Myelomonocytic precursors
￿ Endothelial cells
Subendothelial space Mφ / foam cells / pericytes
Rheumatoid nodules Epitheloid cells and multinucleated giant cells
Lung interstitial space Alveolar Mφ
Mφ, macrophages.  Reproduced with permission from Kinne RW, Stuhlmuller B, Palombo-Kinne E, Burmester GR: The role of macrophages in
rheumatoid arthritis. In Rheumatoid Arthritis. Edited by Firestein GS, Panayi GS, Wollheim FA. New York: Oxford University Press; 2006:55-75 [2]. Table 4. T-cell cytokines acting on Mφ (for example, IL-17)
have been comprehensively reviewed elsewhere [24,25].
Bacterial/viral components and Toll-like receptors
The ability of bacterial toxins or superantigens to initiate the
secretion of Mφ-derived cytokines is relevant in view of a
possible microorganism etiology of RA and in view of side
effects of anti-TNF-α therapy, particularly mycobacterial
infections [26,27]. Lipopolysaccharide (LPS), for example,
binds to Mφ through the CD14/LPS-binding protein receptor
complex and, in vitro, stimulates the production of IL-1β,
TNF-α, and macrophage inflammatory protein-1α. Staphylo-
coccal enterotoxin B (SEB), a potent Mφ activator, enhances
arthritis in MRL-lpr/lpr mice. Anti-TNF-α therapy, in this case,
reverses both the severe wasting effects of SEB and the
incidence of arthritis, indicating that TNF-α is central in this
system. Finally, the staphylococcal enterotoxin A increases
the expression of the Toll-like receptor (TLR)-4 in human
Available online http://arthritis-research.com/content/9/6/224
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Table 3
Monocyte/macrophage functions and their (potential) role in rheumatoid arthritis
Function Mechanisms (Potential) role in rheumatoid arthritis
Clearance of  Binding of immunoglobulins to Fc receptors  Potential clearance of rheumatoid factor but further activation of 
immune complexes (Fc-γ-R I, IIA, IIB, and IIIA) monocytes/Mφ
Opsonization of complexes by complement, leading to binding to Mφ
complement receptors and further cell activation [101,102] (reviewed 
in [2,103])
Notably, inhibition of monocyte activation by Fc-γ-R IIB [102]
Complement  Binding of complement factors to complement  Recognition of activated complement (soluble phase or on 
activation receptors 1 (CD35), 3 (CD11b), and 5a (CD88) immunoglobulin G-immune complexes)
Promotion of phagocytosis and activation of monocytes/Mφ [103]
Phagocytosis of  Conventional (Fc-mediated) → lysosomal  Scavenging of debris but potential import of arthritogenic molecules 
particulate antigens degradation and MHC-II antigen processing [103]
Antigen presentation and activation of CD4+ and CD8+ T cells, possibly 
relevant to disease initiation or perpetuation (spreading of 
autoimmunity) (reviewed in [2])
Coiling phagocytosis → lysosomal degradation  Involved in phagocytosis of Borrelia burgdorferi, active agent of Lyme 
and MHC-I antigen processing arthritis (reviewed in [2])
Clearance of  Removal of pathogens and recognition of  Induction of Mφ-derived cytokines by bacterial toxins or superantigens 
intracellular  apoptotic cells via exposed intracellular  [26,28,103]
pathogens and  membrane components Modulation of Mφ responses by mycobacterial lipoarabinomannan 
apoptotic cells [104,105] or Toll-like receptors [29,106]
Persistence of obligate/facultative intracellular pathogens with 
arthritogenic potential [107,108]
Antigen processing  Enzymatic degradation of antigens and binding  Important cognate functions upon antigen recognition via presentation 
and presentation  of antigenic peptides to MHC molecules and  of antigen on MHC-II molecules [109] and expression of membrane 
transport to the cell surface second signal molecules adjacent to T cells (reviewed in [2])
Chemotaxis and  Attraction of other inflammatory cells and  Positive feedback between Mφ-derived cytokines and chemotactic 
angiogenesis induction of neo-vascularization factors (for example, IL-8 and monocyte chemoattractant protein-1)
Promotion of angiogenesis by IL-8 and soluble forms of adhesion 
molecules (for example, vascular cell adhesion molecule-1 and 
endothelial-leukocyte adhesion molecule-1) [69] 
Wound healing Remodelling of tissue via interaction with  Sustained monocyte recruitment at wound injury sites via monocyte 
fibroblasts chemoattractant macrophage inflammatory protein-1α
Phagocytosis of matrix debris and endogenous production of IL-1, 
TNF-α, and so on as well as post-injury tissue remodelling (reviewed in [2])
Lipid metabolism Mφ synthesis of prostaglandins (PGs) E2 and I2 Pro-inflammatory activity of PGE2 and PGI2 and leukotrienes in 
Expression of scavenger receptor A (uptake of  rheumatoid arthritis, but also autocrine negative feedback through 
oxidized low-density lipoprotein) peroxisome proliferator-activated receptors α and γ (reviewed in [2])
Fish-based diets are associated with clinical improvement of human and 
experimental arthritis (reviewed in [2])
Modulation of T cell-contact-induced production of IL-1β and TNF-α in 
Mφ by apolipoprotein A-I [110]
IL, interleukin; Mφ, macrophage(s); MHC, major histocompatibility complex; TNF-α, tumor necrosis factor-alpha. Reproduced with permission from
Kinne RW, Stuhlmuller B, Palombo-Kinne E, Burmester GR: The role of macrophages in rheumatoid arthritis. In Rheumatoid Arthritis. Edited by
Firestein GS, Panayi GS, Wollheim FA. New York: Oxford University Press; 2006:55-75 [2].monocytes by ligation of major histocompatibility complex-II,
with subsequent enhancement of pro-inflammatory cytokines
by known TLR-4 ligands (for example, LPS [28]).
TLRs are part of the recently discovered cellular pattern-
recognition receptors (PPRs) involved in first-line defense of
the innate immune system against microbial infections. In
addition to bacterial or viral components, some PPRs
recognize host-derived molecules, such as the glycoprotein
gp96, nucleic acids, hyaluronic acid oligosaccharides,
heparan sulfate, fibronectin fragments, and surfactant protein
A (reviewed in [29]). In RA, notably, functional TLR-2 and
TLR-4 are expressed on CD16+ synovial Mφ, peripheral
blood mononuclear cells, and synovial fibroblasts [30]. Also,
their expression can be upregulated by cytokines present in
the inflamed RA joint (for example, IL-1β, TNF-α,
macrophage colony-stimulating factor, and IL-10); this
suggests that activation of synovial cells via TLRs may
contribute to disease processes [29], as supported by
findings in experimental arthritis [31]. On the other hand, the
chronic polyarthritis observed in mice with deletion of the
DNase II gene, whose Mφ are incapable of degrading
mammalian DNA, appears to occur independently of the
nucleic acid-specific TLR-9 [32].
Arthritis Research & Therapy    Vol 9 No 6 Kinne et al.
Page 6 of 16
(page number not for citation purposes)
Figure 2
Paracrine, juxtacrine, and autocrine stimuli (column a) and effector molecules (column b) of macrophage (Mφ) activation in rheumatoid arthritis.
Most of the regulatory products of activated macrophages act on macrophages themselves, creating autocrine regulatory loops whose
dysregulation possibly promotes disease severity and chronicity. The jagged arrow in the T cell indicates the necessity of pre-activating T cells for
effective juxtacrine stimulation of macrophages. AP-1, activation protein; EC, endothelial cells; FB, fibroblasts; ICAM, intracellular adhesion
molecule; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist; LFA-3, lymphocyte function-associated antigen-3; MIF, migration inhibitory
factor; mTNF-α, mouse tumor necrosis factor-alpha; NF-κB, nuclear factor-kappa-B; NK, natural killer cells; sTNF-R, soluble tumor necrosis factor
receptor; TGF-β, transforming growth factor-beta; TNF-α, tumor necrosis factor-alpha; VCAM-1, vascular cell adhesion molecule-1. Reproduced
with permission from Kinne RW, Stuhlmuller B, Palombo-Kinne E, Burmester GR: The role of macrophages in rheumatoid arthritis. In Rheumatoid
Arthritis. Edited by Firestein GS, Panayi GS, Wollheim FA. New York: Oxford University Press; 2006:55-75 [2].
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Table 4
Overview of pro-inflammatory interleukins relevant to macrophage (dys)function in rheumatoid arthritis
Family Cytokine Pro-inflammatory Dual Autocrine Main pathogenetic features
IL-1  IL-1 X - X Predominantly produced by Mφ
Critical mediator of tissue damage
Possesses autocrine features [43,51-53]
IL-18 X - X Predominantly produced by Mφ
Critical pleiotropic mediator of disease
Possesses autocrine features [59-61]
IL-33 X X - Produced by endothelial cells
Important Th2-inducing component in allergy/autoimmunity
Signals via IL-1 receptor-related protein (ST2)
Nuclear factor with transcriptional repressor properties (≈ nuclear 
factor from high endothelial venules) [111-113]
IL-18 inducible IL-32 X - - Pro-inflammatory effects on both myeloid and non-myeloid cells 
[114,115]
IL-2  IL-7 X - - Elevated in RA, although a relative paucity is also possible 
[116,117]
Induces osteoclastic bone loss in mice [118]
IL-15 X - X Produced by Mφ
Important autocrine mediator of disease processes [21,56-58]
IL-21 X - - Only IL-21R is expressed by synovial Mφ and fibroblasts [119]
IL-6  IL-6 X X - Predominantly produced by fibroblasts under the influence of Mφ
Most strikingly elevated cytokine in acute RA, with phase-
dependent differential effects [17,75,76] (reviewed in [2,77])
IL-31 X - - Induces experimental dermatitis [120]
LIF X - - Stimulates proteoglycan resorption in cartilage [121]
Oncostatin M X - - Recruits leukocytes to inflammatory sites and stimulates 
production of metalloprotease (MMP) and tissue inhibitor of MMP 
[121]
IFN type I/ IL-19 X - X Involved in both Th1 and Th2 inflammatory disorders [122,123]
IL-10  Possesses autocrine features [124,125]
IL-20 X - X Overexpressed in psoriasis
Possesses autocrine features [122]
IL-22 X - - Relevant to innate immunity and acute-phase response [126]
IL-24 X - - Possible antagonism with regulatory IL-10 [127]
IL-26 X - - Polymorphism possibly contributes to RA sex-bias susceptibility 
[128]
IL-28, IL-29 X - X Involved in microbial recognition by upregulation of Toll-like 
receptors
Possesses autocrine features [30,129,130]
IL-12  IL-12 X - - Predominantly produced by synovial Mφ and dendritic cells
Promotes Th1 responses (reviewed in [62])
IL-23 X - - Predominantly produced by synovial Mφ and dendritic cells
Shares p40 subunit with IL-12 and possibly antagonizes IL-12 
[63] (reviewed in [62])
IL-27 X X X Produced by Mφ and its neutralization has anti-arthritic effects
Possesses autocrine features [66]
Pro-inflammatory role [67]
IL-17 IL-17 X - - Th0-Th1 lymphokine with pleiotropic, amplifying effects on Mφ in 
arthritis (reviewed in [24,25])
IFN, interferon; LIF, leukemia inhibitory factor; Mφ, macrophages; RA, rheumatoid arthritis. Reproduced with permission from Kinne RW, Stuhlmuller
B, Palombo-Kinne E, Burmester GR: The role of macrophages in rheumatoid arthritis. In Rheumatoid Arthritis. Edited by Firestein GS, Panayi GS,
Wollheim FA. New York: Oxford University Press; 2006:55-75 [2].Hormones
Females are affected by RA at a ratio of approximately 3:1
compared with males and experience clinical fluctuations
during the menstrual cycle and pregnancy, indicating a major
modulating role for sex hormones. Due to their expression of
sex-hormone receptors and their cytokine response upon
exposure to estrogens, monocytes/Mφ are strongly involved
in hormone modulation of RA [33]. Indeed, physiological
levels of estrogens stimulate RA Mφ to the production of the
pro-inflammatory cytokine IL-1, whereas higher levels inhibit
IL-1 production, conceivably mimicking the clinical improve-
ment during pregnancy. Interestingly, selective estrogen recep-
tor  ligands inhibiting nuclear factor (NF)-κB transcriptional
activity (but lacking estrogenic activity) can markedly inhibit
joint swelling and destruction in experimental arthritis [34].
Cytokine stimuli with regulatory effects on macrophages
In addition to pro-inflammatory cytokines, several cytokines
that regulate monocyte/Mφ function in RA have been
described (summarized in the upper left quadrant of
Figure 2). A systematic list of these cytokines is provided in
Table 5. Interestingly, some of these molecules are produced
by Mφ themselves (most notably, IL-10), so that autocrine
regulation may also play a prominent role during the different
clinical phases of RA. Other regulatory cytokines derive from
other cell types present in the inflamed synovial membrane: T
cells (for example, IL-4 and IL-13) or stromal cells (for example,
IL-11). For these molecules, the reader is referred to recent
publications or comprehensive reviews [25,35,36].
Monocyte/macrophage effector molecules in
rheumatoid arthritis
Monocyte/macrophage effector molecules with 
proinflammatory effects in rheumatoid arthritis
Mφ produce a number of pro-inflammatory cytokines, as
schematically shown in the upper right quadrant of Figure 2.
A systematic list of the pro-inflammatory ILs is provided in
Table 4.
Tumor necrosis factor-alpha
TNF-α is a pleiotropic cytokine that increases the expression
of cytokines, adhesion molecules, prostaglandin E2, collage-
nase, and collagen by synovial cells. TNF-α exists in
membrane-bound and soluble forms, both acting as pro-
inflammatory mediators. Transmembrane TNF-α is involved in
local, cell contact-mediated processes and appears to be the
prime stimulator of the R75 receptor [37]. Interestingly, the
transgenic expression of this form is alone sufficient to induce
chronic arthritis [38]; likewise, a mutant membrane TNF-α,
which uses both R55 and R75 receptors, can cause arthritis.
Conversely, the soluble form of TNF-α, shed via MMP
cleavage from the membrane-bound form, primarily stimulates
the R55 receptor, acting transiently and at a distance [37].
In RA, TNF-α is mostly produced by Mφ in the synovial
membrane and at the cartilage-pannus junction and possibly
occupies a proximal position in the RA inflammatory cascade
[39]. While an average of approximately 5% of synovial cells
express TNF-α mRNA/protein  in situ [40], the degree of
TNF-α expression in the synovial tissue depends upon the
prevailing histological configuration, resulting in different
clinical variants [41]. Different disease stages and clinical
variants are also reflected in serum and synovial fluid levels of
TNF-α [42].
The critical importance of TNF-α in RA is supported by
several experimental observations: (a) TNF-α in combination
with IL-1 is a potent inducer of synovitis [43], (b) transgenic,
deregulated expression of TNF-α causes the development of
chronic arthritis [44], (c) TNF-α is produced in synovial
membrane and extra-articular/lymphoid organs in experi-
mental arthritides, mimicking the systemic character of RA
[2], (d) neutralization of TNF-α suppresses experimental
arthritides [39,43], and (e) administration of chimeric/human-
ized anti-TNF-α monoclonal antibodies or TNF-α receptor
constructs has shown remarkable efficacy in acute disease
and retardation of radiographic progression [3,7,11].
As an interesting development, the analysis of gene
expression in monocytes of anti-TNF-α-treated patients with
RA may represent a powerful tool to identify regulation
patterns applicable for diagnosis and therapy stratification or
monitoring [45,46] (Stuhlmuller B, Hernandez MM, Haeupl T,
Kuban RJ, Gruetzkau A, Voss JW, Salfeld J, Kinne RW,
Burmester GR, unpublished data). A reasonable expectation
is that gene analyses also provide means to predict which
patients are future responders to anti-TNF-α therapy.
Tumor necrosis factor-alpha receptors
TNF receptors are found in synovial tissue and fluid of patients
with RA, especially in cases of severe disease [39]. There are
two known TNF receptors, the R55 (TNF-R1) (high-affinity
receptor) and the R75 (TNF-R2) (low-affinity receptor), which
are expressed by both synovial Mφ and fibroblasts [47,48].
The two TNF receptors can operate independently of one
another, cooperatively, or by ‘passing’ TNF-α to one another
[37], a complexity that may explain the tremendous sensitivity
of target cells (such as Mφ) to minute concentrations of TNF-
α. TNF receptors can also be shed, binding to soluble TNF-α
and hence acting as natural inhibitors in disease. Recent
studies have demonstrated that TNF-R1 may be primarily
responsible for pro-inflammatory effects of TNF-α, whereas
TNF-R2 may predominantly mediate anti-inflammatory effects
of TNF-α [48] (reviewed in [49]). Thus, selective blockade of
TNF-R1, instead of broad blockade of all effects of TNF-α,
may become an attractive therapeutic approach [48,50].
Interleukin-1
In the RA synovial membrane, IL-1 is found predominantly in
CD14+ Mφ [51]; also, IL-1 levels in the synovial fluid
significantly correlate with joint inflammation [52]. The two
existing forms of IL-1 (IL-1α and IL-1β) show some differ-
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inflammatory regulation of the IL-1β promoter, and secretion of
inactive pro-IL-1β versus expression of membrane-bound IL-
1α activity) but also strong similarities (that is, three-
dimensional structures of the essential domains, molecular
masses of pro-peptides, and mature-form processing protea-
ses), resulting in almost identical binding capacity to the IL-1
receptors and comparable function. In arthritis, IL-1 appears to
mediate a large part of the articular damage, as it profoundly
influences proteoglycan synthesis and degradation [43,53]. At
the same time, IL-1 induces the production of MMP-1 and
MMP-3 and enhances bone resorption; this is compatible with
recent evidence from arthritis models and human RA
suggesting that the tissue-destruction capacities of IL-1β may
outweigh its genuine role in joint inflammation [53].
Interleukin-1 receptors
The IL-1 type I receptor (IL-1R1), which mediates cell
activation via IL-1R accessory protein and IL-1 receptor-asso-
ciated kinase (IRAK), is found on numerous cells in the
synovial tissue of patients with RA [54]. In contrast, the type II
receptor (IL-1R2) (also found in soluble form in serum), which
lacks cell-activating properties and acts exclusively as a decoy
receptor, is low in synovial tissue [55]. Similarly, IL-1RA, a
soluble protein that blocks the action of IL-1 by binding to the
type I receptor without receptor activation, has been detected
only sporadically in RA synovial samples. In RA, the balance
between IL-1 and its physiological inhibitor IL-1RA is therefore
shifted in favor of IL-1, indicating a dysregulation crucial in
promoting chronicity [53]. However, therapeutic application of
IL-1RA (anakinra) appears to be only modestly effective in RA
(reviewed in [56]). Therefore, it remains to be clarified whether
the IL-1 pathway is a less suitable therapeutic target than TNF-
α (for example, due to functional redundancy in the IL-1
receptor superfamily) or whether the biological molecule IL-
1RA is suboptimal for therapy.
Interleukin-15
IL-15, a cytokine of the IL-2 family with chemoattractant
properties for memory T cells, is produced by lining layer cells
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Table 5
Overview of anti-inflammatory cytokines relevant to macrophage (dys)function in rheumatoid arthritis
Anti-inflammatory Dual Autocrine Main pathogenetic features
IL-1RA X - X Produced by differentiated Mφ and upregulated by pro-inflammatory mediators, 
including IL-1 itself or granulocyte macrophage colony-stimulating factor
Autocrine contribution to the termination of inflammatory reactions [54,55] 
(reviewed in [53,56])
IL-4 X - - Strong regulator of Mφ functions but virtually absent in synovial tissue 
[73,131-133]
IL-10 X - X Produced by synovial Mφ
Strong regulator of Mφ functions but relatively deficient in RA
Possesses autocrine features [73,74]
IL-11 X X - Regulator of Mφ functions in a paracrine regulatory loop with synovial fibroblasts 
[36,134]
IL-13 X X - Selective regulator of Mφ functions
Improves experimental arthritis (reviewed in [2,91])
IL-16 X X - Known as an anti-inflammatory molecule [135,136], IL-16 also has pro-
inflammatory properties (that is, correlates with metalloprotease-3 levels, 
progression of joint destruction, and levels of other pro-inflammatory cytokines) 
[137,138].
IFN-β X - - Clear anti-inflammatory and anti-destructive effects in experimental arthritides
Therapy attempts in human RA thus far have been unsuccessful [149].
TGF-β X X X Produced by Mφ [78-80]
Main regulator of connective tissue remodelling
Potent inducer of hyaluronan synthase 1
Induces synovial inflammation (reviewed in [80]) but also suppresses acute and 
chronic arthritis [81,82]
Induces inflammation and cartilage degradation in a rabbit model [140]
Possesses autocrine features
MMP can affect TGF-β via shedding of latent TGF-β attached to decorin 
(disease-enhancing loop).
IFN-β, interferon-beta; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist; Mφ, macrophage(s); RA, rheumatoid arthritis; TGF-β, transforming
growth factor-beta. Reproduced with permission from Kinne RW, Stuhlmuller B, Palombo-Kinne E, Burmester GR: The role of macrophages in
rheumatoid arthritis. In Rheumatoid Arthritis. Edited by Firestein GS, Panayi GS, Wollheim FA. New York: Oxford University Press; 2006:55-75 [2]. (including Mφ) and is increased in RA synovial fluid [57].
Notably, peripheral or synovial T cells stimulated with IL-15
induce Mφ to produce IL-1β, TNF-α, IL-8, and monocyte
chemotactic protein-1 [21,57] but not the regulatory IL-10.
Because IL-15 is also produced by Mφ themselves, this
cytokine may (re)stimulate T cells, possibly self-perpetuating
a pro-inflammatory loop [57]. The expression of IL-15 in the
RA synovial membrane, its biological function, and its
successful targeting in experimental arthritis have generated
large expectations on the use of a fully humanized anti-IL-15
antibody in clinical trials [56-58].
Interleukin-18
In the RA synovial membrane, this cytokine of the IL-1 family
is expressed in CD68+ Mφ contained in lymphoid aggregates.
CD14+ Mφ of the RA synovial fluid also express the IL-18
receptor [59]. The pro-inflammatory role of IL-18 in arthritis
(and its potential suitability as a therapeutic target in RA) is
indicated by the following findings: (a) IL-18 treatment
markedly aggravates experimental arthritis [59], (b) intra-
articular overexpression of IL-18 induces experimental arthritis,
(c) IL-18 is involved in the development of experimental
streptococcal arthritis (a strongly Mφ-dependent model), (d)
IL-18 is selectively overexpressed in the bone marrow of
patients with juvenile idiopathic arthritis and Mφ activation
syndrome [5], (e) IL-18 can stimulate osteoclast formation
through upregulation of RANKL (receptor activator of NF-κB
ligand) production by T cells in RA synovitis, and (f) IL-18
mediates its action via classic induction of TNF-α, GM-CSF,
and interferon (IFN)-γ [59] or functional Toll-like receptors
TLR-2 and TLR-4 in synovial cells [30] or else through the
induction of synovial acute-phase serum amyloid proteins.
The clinical relevance of synovial IL-18 is emphasised by its
correlation with the systemic levels of C-reactive protein
(CRP); also, IL-18 and CRP decrease in parallel in synovial
tissue and serum following effective treatment with disease-
modifying anti-rheumatic drugs [60]. In addition, peripheral
blood mononuclear cells of RA patients show low levels of
the IL-18 binding protein (a natural inhibitor of IL-18) and
reduced sensitivity to stimulation with IL-12/IL-18, indicating
profound dysregulation of the IL-18 system [61].
Interleukin-23
The genuine role of IL-23, a cytokine of the IL-12 family
predominantly produced by Mφ or dendritic cells, is unclear
due to the sharing of the p40 subunit with IL-12 [62]. IL-23
has prominent pro-inflammatory functions, since transgenic
expression in mice leads to multi-organ inflammation and
premature death. IL-23 promotes various T-cell responses
potentially relevant to RA [62]. Recent studies in experimental
arthritis have demonstrated that mice lacking only IL-12
(p35–/–) show exacerbated arthritis, whereas mice lacking
only IL-23 (p19–/–) are completely protected from arthritis
[63]. In addition, activation of Mφ derived from arthritis-
susceptible rats is paradoxically associated with reduced
levels of pro-inflammatory mediators but high expression of
IL-23 (p19), whereas non-susceptible rats show the inverse
phenotype. If these findings were transferable to human RA,
IL-23 would have a pro-inflammatory role and IL-12 a
protective one. At the present time, it is unclear whether
these findings fit into the recently introduced M1/M2
paradigm of differential Mφ activation [64,65] and especially
whether this paradigm can be exploited for a better
understanding of the role of Mφ in RA.
Interleukin-27
IL-27, another cytokine of the IL-12 family, is expressed by
monocytes/Mφ following common inflammatory stimuli and
displays a variety of pro- and anti-inflammatory properties
[66]. In support of a pro-inflammatory role in arthritis,
neutralizing antibodies against IL-27p28 suppress experi-
mental arthritis [67].
Chemokines and chemokine receptors
Chemokines (subdivided into the CXC, CC, C, and CX3C
families) are small proteins specialized in differential recruit-
ment of leukocyte populations via a number of trans-
membrane receptors. Chemokines not only favor monocyte
influx into inflamed tissue, but also play a key role in activa-
tion, functional polarization, and homing of patrolling mono-
cytes/Mφ [65]. Notably, monocytes/Mφ express only select
types of the numerous chemokine receptors (for example,
CCR1, 2, 5, 7, and 8 as well as CX3CR1), representing a
partially specific basis for prominent trafficking of
monocyte/Mφ in arthritis. In RA, synovial Mφ produce several
chemokines (for example, CCL3 [or Mφ inflammatory protein
1α], CCL5 [or RANTES], and CX3CL1 [or fractalkine]) and
at the same time carry chemokine receptors, indicating the
presence of autocrine loops in disease (reviewed in [68]). At
the same time, chemokines are upregulated by the Mφ-
derived TNF-α and IL-1. Significantly, some chemokines
expressed in synovial Mφ (for example, IL-8 and fractalkine)
are powerful promoters of angiogenesis, thus providing a link
between Mφ activation and the prominent neo-vascularization
of the RA synovium [69]. In RA, angiogenesis may be further
promoted via activation of Mφ by advanced glycation end
products, whereas thrombospondin-2 seems to
downregulate angiogenesis. Because the enlargement of the
vascular bed potentiates the influx of activated monocytes,
down-modulation of the chemokine system represents a
multi-potential target of anti-rheumatic therapy, as indicated
by the promising results of treatment with a CCR1 antagonist
in RA [68].
Macrophage migration inhibitory factor
One of the first ILs ever discovered, migration inhibitory factor
(MIF), is an early-response cytokine abundantly released by
Mφ. MIF stimulates a number of Mφ functions in an autocrine
fashion (for example, secretion of TNF-α, phagocytosis, and
generation of reactive oxygen species [ROS]). In addition,
MIF confers resistance to apoptosis in Mφ and synovial
fibroblasts, thus prolonging the survival of activated, disease-
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synovial tissue in correlation with disease activity. Also,
polymorphisms in the promoter or coding region of the human
MIF gene are associated with features of juvenile idiopathic
arthritis or adult RA [70].
Monocyte/macrophage effector molecules with anti-
inflammatory/regulatory effects in rheumatoid arthritis
Mφ also produce anti-inflammatory cytokines, most notably
IL-RA and IL-10, both cytokines engaged in autocrine
regulatory loops (shown in the lower right quadrant of
Figure 2) (Table 5).
Interleukin-1 receptor antagonist
Differentiated Mφ constitutively express IL-1RA, which is
upregulated by pro-inflammatory mediators, including IL-1
itself or GM-CSF, and induces strong anti-inflammatory
effects. By means of this feedback mechanism, Mφ therefore
contribute to the termination of inflammatory reactions
(reviewed in [71,72]) (see above).
Interleukin-10
IL-10, a Th2- and Mφ-derived cytokine with clear autocrine
functions, reduces HLA-DR expression and antigen
presentation in monocytes and inhibits the production of pro-
inflammatory cytokines, GM-CSF, and Fc-γ receptors by
synovial Mφ. Consistently with cytokine and chemokine
downregulation, IL-10 clearly suppresses experimental
arthritis. In spite of IL-10 elevation in serum and synovial
compartments of patients with RA [73], some studies
suggest a relative deficiency of IL-10 [74]. A combined IL-4/IL-10
deficiency probably tilts the cytokine balance to a pro-
inflammatory predominance. In addition, the ex vivo
production of IL-10 by RA peripheral blood mononuclear cells
is negatively correlated with radiographic joint damage and
progression of joint damage, suggesting that high IL-10
production is protective in RA. Similarly to IL-4, however,
treatment with recombinant IL-10 does not improve RA. This
may be partially explained by upregulation of the pro-
inflammatory Fc-γ receptors I and IIA on monocytes/Mφ
(reviewed in [2]).
Monocyte/macrophage effector molecules with dual
effects in rheumatoid arthritis
Cytokines with a dual role are indicated in Tables 4 and 5.
Interleukin-6
IL-6 is the most strikingly elevated cytokine in RA, especially
in the synovial fluid during acute disease [75]. The acute rise
is consistent with the role of IL-6 in acute-phase responses
(Table 1). However, while IL-6 levels in the synovial fluid
correlate with the degree of radiological joint damage, and
IL-6 and soluble IL-6 receptors promote the generation of
osteoclasts, this cytokine has phase-dependent effects; for
example, it protects cartilage in acute disease but promotes
excessive bone formation in chronic disease. While IL-6 is
mostly produced by synovial fibroblasts and only partially by
Mφ, two findings suggest that the striking IL-6 rise is a
prominent outcome of Mφ activation: (a) the morphological
vicinity of IL-6-expressing fibroblasts with CD14+ Mφ in the
RA synovial tissue (reviewed in [2]) and (b) co-culture studies
showing that IL-1 stimulates IL-6 production [17]. The role of
IL-6 in experimental arthritis and the anti-arthritic effects of
anti-IL-6 receptor antibodies suggest a role for anti-IL-6
therapy in RA [76] (reviewed in [77]).
Transforming growth factor-beta
In RA, Mφ express different transforming growth factor-beta
(TGF-β) molecules and TGF-β receptors in the lining and
sublining layers, at the cartilage-pannus junction, and in the
synovial fluid [78-80]. The pro-inflammatory effects of TGF-β
are substantiated by induction of Mφ expression of Fc-γ
receptor III (which elicits the release of tissue-damaging
ROS) and promotion of monocyte adhesion and infiltration
during chronic disease (reviewed in [80]). At the same time,
TGF-β has anti-inflammatory properties; for example, it
counteracts some IL-1 effects, including phagocytosis of
collagen and possibly MMP production. A protective role of
TGF-β in RA is also suggested by the association between
TGF-β polymorphism and disease severity; that is, alleles
associated with low TGF-β expression are correlated with
stronger inflammation and poorer outcome [81]. Likewise,
experimental arthritis is significantly ameliorated by activation
of TGF-β via adenoviral expression of thrombospondin-1 [82].
The effects of TGF-β on tissue inhibitor of MMP (TIMP) are
also unclear, as the regulation of MMP and TIMP may depend
on different tissue domains (superficial versus deep cartilage
layers) and may vary for intra- or extracellular digestion of
collagen (reviewed in [2]).
Treatment of human rheumatoid arthritis with
conventional anti-macrophage approaches
The role of Mφ-derived cytokines in the perpetuation of RA,
the pathophysiological dichotomy between joint inflammation
and cartilage destruction, and the crucial significance of
activated synovial Mφ in relation to permanent joint damage
[1] have led to a radical re-evaluation of the conventional anti-
inflammatory and disease-modifying treatments in relation to
Mφ parameters in order to potentiate therapeutic effects (for
example, via combination approaches [83]) and reduce side
effects. For anti-Mφ effects of conventional anti-rheumatic
therapy in RA (including methotrexate, leflunomide, anti-
malarials, gold compounds, corticosteroids, and non-steroidal
anti-inflammatory drugs), the reader is referred to a recent
comprehensive review [11]. Recent findings show that con-
ventional and specific anti-rheumatic treatments predominantly
target sublining rather than lining Mφ; also, different thera-
peutic approaches seem to result in similar histological
changes in the inflamed synovial membrane, including signifi-
cant reduction of sublining Mφ. This, in turn, is significantly
correlated with the degree of clinical improvement [11,12].
Thus, different pathogenetic mechanisms may funnel into
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Mφ and providing the rationale for targeted anti-Mφ therapy.
Non-conventional and experimental anti-
macrophage therapy
Counteraction of monocyte/macrophage activation at a
cellular level
Apoptosis-inducing agents
Physical elimination of disease-relevant cells (for example,
activated Mφ or osteoclasts) by apoptosis is advantageous
because it circumvents secondary tissue damage by restrain-
ing cellular organelles in apoptotic vesicles. Phagocytic
incorporation of liposome-encapsulated non-amino-bisphos-
phonates by activated monocytes, for example, induces
apoptosis in these cells [84] (Figure 3). Systemic application
of encapsulated bisphosphonates in experimental arthritis not
only counteracts joint swelling, but also prevents local joint
destruction and subchondral bone damage [85]; in addition,
it shows protective effects on remote bone damage. Studies
in RA show that a single intra-articular administration of
clodronate liposomes leads to Mφ depletion and decreased
expression of adhesion molecules in the lining layer of RA
synovial tissue [86]. Selective targeting of activated Mφ has
also been demonstrated using either apoptosis-inducing
immunotoxins coupled to anti-Fc-γ receptor I (CD64) anti-
bodies or folate receptor-mediated targeting (reviewed in
[2]). In general, liposome encapsulation can also be exploited
for selective delivery of Mφ-modulating drugs [87] (reviewed
in [2]) or gene therapy constructs (reviewed in [88]).
Control of gene transcription
The transcription of most cytokine genes in monocytes/Mφ
depends on the activation of NF-κB and NF-κM transcription
factors or that of the activator protein-1 (AP-1) complex. In
RA synovial Mφ, the expression of NF-κB is more pronounced
than that of AP-1, a selectivity that may bear important
therapeutic implications [89]. Accordingly, the anti-arthritic
effects of IL-4 may be based on the selective suppression of
NF-κB in Mφ. IL-10 also downregulates the production of pro-
inflammatory monokines, inhibiting the nuclear factors NF-κB,
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Figure 3
Potential and established approaches for modulation of monocyte/macrophage (Mφ) functions in rheumatoid arthritis. COX-2, cyclooxygenase-2;
EC, endothelial cells; FB, fibroblasts; ICAM-1, intracellular adhesion molecule-1; IFN-β, interferon-beta; IL, interleukin; IL-1RA, interleukin-1 receptor
antagonist; iNOS, inducible nitric-oxide synthase; mAbs, mononuclear antibodies; cPLA2, cytosolic phospholipase A2; MMP, metalloprotease; MTX,
methotrexate; NF-κB, nuclear factor-kappa-B; PGE2, prostaglandin E2; PPAR-γ, peroxisome proliferator-activated receptor-gamma; ROS, reactive
oxygen species; TNF-α, tumor necrosis factor-alpha. Reproduced with permission from Kinne RW, Stuhlmuller B, Palombo-Kinne E, Burmester GR:
The role of macrophages in rheumatoid arthritis. In Rheumatoid Arthritis. Edited by Firestein GS, Panayi GS, Wollheim FA. New York: Oxford
University Press; 2006:55-75 [2].
Mφ
EC
FB
T-cell
5) Blockade of effector molecules
- Inhibition of PGE2formation (selective cPLA2 or COX-2 inhibitors)
- Inhibition of iNOS (e.g., iminohomopiperidinium salts)
- Inhibition of ROS formation (e.g., metal compounds)
- Inhibition of tissue degradation (e.g., selective MMP-inhibitors)
2) Blockade of cell-cell interaction
- T-cell/Mφ (e.g., anti-CD40L, anti-CD4)
- Fibroblast/Mφ (e.g., anti-TNF-α)
1) Blockade of monocyte recruitment
- Anti-adhesion molecules (e.g., anti-ICAM-1, anti-CD18)
- Chemokine inhibitors (e.g., anti-IL-8, anti-CX3CL1)
4) Cytokine-based therapy
- Anti-TNF-α approaches (e.g., mAbs, TNF-receptor constructs;
  Rolipram; conventional anti-rheumatics)
- Anti-IL-1 approaches (e.g., IL-1RA; recomb./gene therapeutic)
- Anti-IL-15, anti-IL-18 etc.
- Regulatory cytokines (e.g., IFN-β, IL-10)
3) Counteraction of macrophage activation
    at a cellular level
- Apoptosis-inducing agents (free/encapsulated non-amino
  bisphosphonates; anti-Fc-γ-receptor I immunotoxin)
- Osteoclast function-blocking amino bisphosphonates 
- Encapsulated macrophage-modulating drugs (e.g., MTX)
- Regulatory transcription factors (e.g., PPAR-γ)
- Gene therapy (e.g., NF-κB decoys)
- Folate receptor-mediated targetingAP-1, or NF-IL-6. Unlike IL-4, IL-10 can also enhance
degradation of the mRNA for IL-1 and TNF-α (reviewed in
[2]). In general, therefore, targeted inhibition of ‘pro-
inflammatory’ signal transduction pathways in Mφ represents
an attractive therapeutic approach [90].
Gene therapy in experimental arthritis
Gene therapy has been applied in experimental arthritis
models to counteract Mφ-derived IL-1 and TNF-α or to
deliver/overexpress protective IL-1RA, soluble IL-1 type I
receptor-IgG fusion protein, and type I soluble TNF-α
receptor-IgG fusion protein. This has been extended to (Mφ-
derived) anti-inflammatory cytokines (that is, IL-4, IL-10, IL-13,
IFN-β, or TGF-β) and to ‘molecular synovectomy’ (either by
expression of herpes simplex virus-thymidine kinase with
subsequent administration of ganciclovir or by overexpression
of Fas-ligand/inhibitors of nuclear translocation of NF-κB,
resulting in synovial cell apoptosis [88,91,92]). Therefore,
gene therapy aimed at neutralizing pro-inflammatory Mφ
products, overexpressing Mφ-regulating mediators, or simply
eliminating overly activated Mφ remains promising for the
treatment of arthritis.
Conclusion
The multitude and abundance of Mφ-derived mediators in RA
and their paracrine and autocrine effects (including those
directed to other cells of the myeloid lineage) indicate that
Mφ are local and systemic amplifiers of disease severity and
perpetuation. The main local mechanisms include (a) self-
perpetuating chemokine-mediated recruitment of inflammatory
cells, (b) cytokine-mediated activation of newly immigrated
inflammatory cells, (c) cell contact-mediated activation of
neighboring inflammatory cells, (d) cytokine- and cell contact-
mediated secretion of matrix-degrading enzymes, (e) activa-
tion of mature dendritic cells and cytokine-mediated differen-
tiation of Mφ (and possibly B cells, T cells, and mesenchymal
cells) into antigen-presenting cells, with possible effects on
spreading of autoimmunity to cryptic epitopes, (f) neo-
vascularization, with potentiation of cellular and exudatory
mechanisms, and (g) (trans)differentiation of Mφ into
osteoclasts involved in subchondral bone damage. At a
systemic level, amplification of disease can proceed at least
through the following mechanisms: (a) acute-phase response
network, (b) systemic production of TNF-α, (c) anomalies in
bone marrow differentiation, and (d) chronic activation of
circulating monocytes.
Although uncovering the etiology of disease remains the
ultimate goal of research, the efforts in understanding how
activated Mφ influence disease have led to optimization
strategies to selectively target activated Mφ in RA (Figure 3).
This approach has at least two advantages: (a) striking the
very cell population that mediates/amplifies most of the
irreversible cartilage destruction and (b) minimizing adverse
effects on other cells that may have no (or marginal) effects
on joint damage.
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